7 assets in Gaucher Disease Type III

Therapeutic assets addressing Gaucher Disease Type III, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
.Alpha.-D-Glucosyl-N-Acylsphingosine Glucohydrolase Gaucher Disease Type III	Sanofi	P3	BB (64)
Eliglustat Gaucher Disease Type III	Sanofi	P3	BB (64)
Venglustat Gaucher Disease Type III	Sanofi	P3	B (58)
High-Dose Can103 Gaucher Disease Type III	CANbridge (Suzhou) Bio-pharma Co., Ltd.	P1/2	CCC (48)
Low-Dose Can103 Gaucher Disease Type III	CANbridge (Suzhou) Bio-pharma Co., Ltd.	P1/2	CCC (48)
Iduronidase, .Alpha.-L-(8-Histidine) (Human) Gaucher Disease Type III	University of California, San Francisco	P1	CC (43)
Ambroxol Gaucher Disease Type III	Agyany Pharma LTD	N/A	D (30)